Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota spores, live-brpk
- Development stage
- Approved
- Lead developer
- Nestlé Health Science
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
fecal microbiota spores, live-brpk (marketed as Vowst, formerly known as SER-109) is an orally administered live biotherapeutic product consisting of a purified consortium of bacterial spores (primarily Firmicutes) derived from healthy human donor fecal matter. It is developed by Seres Therapeutics and Nestlé Health Science (which acquired full global rights to the product in 2024). Vowst is FDA-approved for the prevention of recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI. The therapeutic works by restoring the gut microbiome, thereby increasing colonization resistance against C. difficile.
- Brand names
- Vowst
- Other names
- VOSfecal microbiota spores, live-brpklive-brpk
Beyond the preview
Go deeper on fecal microbiota spores, live-brpk.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota spores, live-brpk.